ONO-8539
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout ONO-8539
ONO-8539 is a phase 1 stage product being developed by Ono Pharmaceutical for Acid Reflux. The current trial status is completed. This product is registered under clinical trial identifier NCT01705275. Target conditions include Acid Reflux.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01705275 | Phase 1 | Completed |
| NCT01707901 | Phase 1 | Completed |
Competing Products
20 competing products in Acid Reflux
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Low Dose REN001 + High Dose REN001 | OnKure Therapeutics | Phase 1 | 25 |
| LJN452 + Placebo to LJN452 | Novartis | Phase 2 | 52 |
| Insulin (Aspart Insulin [Novolog], Regular Insulin) | Novo Nordisk | Pre-clinical | 22 |
| Pantoprazole | Pfizer | Approved | 84 |
| Recombinant human acid sphingomyelinase | Sanofi | Phase 1 | 32 |
| Olipudase alfa | Sanofi | Pre-clinical | 22 |
| insulin glargine+ glulisine + NPH + Regular insulin | Sanofi | Approved | 84 |
| Ataluren | Sanofi | Phase 2 | 51 |
| rhASM + rhASM + rhASM + rhASM + rhASM | Sanofi | Phase 1 | 32 |
| Omeprazole/sodium bicarbonate + omeprazole magnesium + sodium bicarbonate | Bayer | Phase 3 | 74 |
| Omeprazole/sodium bicarbonate + omeprazole magnesium (20 mg equivalent) | Bayer | Phase 3 | 74 |
| Zegerid + Prilosec OTC™ Tablets | Bayer | Phase 3 | 74 |
| A3384 | Ipsen | Phase 2 | 49 |
| Clinolipid + Intralipid | Baxter | Approved | 82 |
| Clinolipid + Intralipid | Baxter | Approved | 82 |
| Carglumic Acid | Recordati | Pre-clinical | 20 |
| Cholic acid | Mirum Pharmaceuticals | Phase 3 | 74 |
| AAV2-hAADC | PTC Therapeutics | Phase 2 | 49 |
| gene therapy | PTC Therapeutics | Phase 1/2 | 38 |
| Cholbam | Mirum Pharmaceuticals | Pre-clinical | 20 |